New drug for heart disease shows promise for cats and humans

December 22, 2016 by Rob Warren
UC Davis veterinary cardiologist Joshua Stern performs an echocardiogram on a cat, assisted by animal health technicians Heather Schrader, right, and Judy Schettler. Credit: Don Preisler/UC Davis

A new drug shows promise for treating heart disease in cats and humans, according to research by a team including veterinarians at the University of California, Davis, School of Veterinary Medicine.

The novel drug, MYK-461, proved effective in a study of five cats with a naturally occurring form of inherited hypertrophic cardiomyopathy (HCM), a currently incurable disease that also affects humans. A paper describing the work was published Dec. 14 in the journal PLOS ONE.

HCM is the most common form of feline heart disease and results in thickening of the walls of the heart ventricles and altering of heart function. It frequently leads to fatal consequences. Cats with this disease may suffer , and sudden death. In humans, HCM is a frequent cause of that can even afflict seemingly healthy young athletes.

HCM affects approximately one in 500 people and was recently reported to affect a startling one in seven cats. More than 1,500 genetic mutations have been associated with the disease in humans, creating challenges for researchers. However, veterinary scientists are making strides in identifying the best treatment options for the disease since the cat condition and human condition are so similar.

In the study, treatment with MYK-461 eliminated left ventricular obstruction in five cats with HCM. The is the first in its class and uniquely addresses the functional changes that are seen in and feline HCM.

"This is an exciting discovery for both animals and humans – an excellent representation of the One Health concept in action," said Associate Professor Joshua Stern, chief of the Cardiology Service at the UC Davis veterinary hospital. "The positive result in these five cats shows that MYK-461 is viable for use in cats as a possible option to halt or slow the progression of HCM."

MYK-461 was already shown to stop the thickening of the ventricle walls in mice.

Current treatment for cats with HCM is largely symptomatic. There is no preventative therapy for HCM that is shown to change the course of .

"There has been little to no progress in advancing the treatment of HCM in humans or animals for many years," Stern said. "This study brings new hope for cats and people."

With this proof of concept that the drug is viable for use in cats, UC Davis hopes to conduct a clinical trial in the near future, which could determine if MYK-461 has the potential to become the accepted protocol for care of with HCM.

Explore further: Researchers study stem-cell therapy for feline kidney disease

More information: Joshua A. Stern et al. A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy, PLOS ONE (2016). DOI: 10.1371/journal.pone.0168407

E. M. Green et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice, Science (2016). DOI: 10.1126/science.aad3456

Related Stories

Researchers study stem-cell therapy for feline kidney disease

January 9, 2014
Chronic kidney disease in older cats is the focus of a fifth clinical trial under way at Colorado State University's James L. Voss Veterinary Teaching Hospital, where veterinarians are exploring novel stem-cell therapy that ...

Cat stem cell therapy gives humans hope

February 2, 2016
By the time Bob the cat came to the UC Davis veterinary hospital, he had used up most of his nine lives. Afflicted with a painful oral inflammatory disorder, Bob had already lost all of his teeth in an effort to treat the ...

Chronic kidney disease in cats—Expert guidance on a quality of life issue

March 2, 2016
Chronic kidney disease (CKD) is a common, complex and progressive disease that is estimated to affect more than a third of cats over 10 years of age. Affected cats often present with a variety of clinical signs and complications ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.